Hyperhidrosis Clinical Trial
Official title:
Cardiac Autonomic Changes After Endoscopic Thoracic Sympathectomy For Essential Palmar Hyperhidrosis: Results Of A Prospective, Randomized Study
Essential palmar hyperhidrosis (EPH) is a pathological condition of excessive sweating of
the hands due to an unexplained over-activity of the T2 and T3 sympathetic fibers. Endoscopy
Thoracoscopic Sympathectomy (ETS) is the treatment of choice in patients with EPH refractory
to medical treatment .
The cardiac sympathetic activity is mainly controlled by cervical sympathetic fibers but
anatomic studies have showed that "accessory" fibers from the T2 and T3 sympathetic ganglia
come to the heart and influence its function.
Heart Rate Variability (HRV) is a simple and non-invasive method based on electrocardiogram
to evaluate the sympathovagal balance at the sino-atrial level. Several studies have found
that ETS caused a decrease of heart rate (HR), an increase of HR variability (HRV) and a
shift of sympathovagal balance toward parasympathetic tone but remains unclear if these
changes are associated with the extend of ETS.
Thus, in the present study the investigator performed a prospective analysis of HRV function
in patients with EPH undergoing different sympathetic denervations as sympathectomy and
sympathicotomy with the hypothesis that cardiac autonomic changes could be associated with
the extend of sympathetic resection.
It was an unicenter prospective study performed at Thoracic Surgery Unit of Second
University of Naples. Patients with severe EPH were randomly assigned to Sympathectomy or
Sympathicotomy Group in 1:1 ratio .
Bilateral ETSs were performed in a one-stage procedure by the same surgeon. General
anaesthesia using single-lung ventilation technique was performed and patient was placed in
standard lateral thoracotomy position. Immediately after the induction of anaesthesia, a
local infiltration with 2% lidocaine and epinephrine was injected at each port 5 minutes
before the incision to reduce postoperative pain. The first port was placed in the 3th
intercostal space below and anterior to inferior angle of scapula and through that a 10 mm
30 degree camera was inserted. A second 5 mm working port was placed at the same intercostal
space in the anterior axillary line. After identification of sympathetic chain, in
Sympathectomy Group the T3 ganglion was excised at the top of the third rib while in
Sympathicotomy Group the sympathetic chain was resected between T2-T3 ganglia at the same
level but the T3 ganglion was left intact. At the end of the procedure, a 16 F drainage was
inserted through the port and the lung was re-inflated to allow the air drainage from
pleural cavity and to prevent pneumothorax. The drain was subsequently removed.
All measurements on cardiac autonomic function were performed one week before ETS and
different post-operative time-points (7 days, 1, 3 and 6 months after ETS). The results were
prospectively registered and then retrospectively analyzed.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04924036 -
Qbrexza Cloths for Hyperhidrosis of Amputation Sites
|
Phase 2 | |
Recruiting |
NCT05102396 -
Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?
|
Phase 2 | |
Recruiting |
NCT04178161 -
Image Guided Targeted Photoablation for the Treatment of Localized Hyperhidrosis
|
N/A | |
Completed |
NCT02565732 -
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
|
Phase 2 | |
Completed |
NCT02552199 -
A Non-Interventional Study To Assess Sweating
|
||
Recruiting |
NCT01930604 -
Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
|
Phase 2 | |
Completed |
NCT01811004 -
Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis
|
N/A | |
Completed |
NCT01671800 -
Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating
|
Phase 1 | |
Completed |
NCT01956591 -
Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis
|
N/A | |
Completed |
NCT01934153 -
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT06113978 -
Thoracoscopic Sympathetic Chain Interruption for Palmar Hyperhidrosis in Patients Below 18
|
N/A | |
Completed |
NCT04906655 -
An Open Label Study for Palmar Hyperhydrosis
|
Phase 2 | |
Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
Completed |
NCT02563899 -
Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
|
Phase 2 | |
Withdrawn |
NCT05546710 -
miraDry Post Market Tumescent Anesthesia Study
|
N/A | |
Completed |
NCT02016885 -
A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
|
Phase 2 | |
Completed |
NCT00168480 -
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
|
Phase 4 | |
Completed |
NCT03416348 -
Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2
|
Phase 1 | |
Completed |
NCT02973659 -
The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.
|
N/A | |
Recruiting |
NCT05805696 -
Treatment and Mapping of Impostor Phenomenon
|
N/A |